ReviewCurrent opinion in HIV and AIDS2009
Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?
Review in Current opinion in HIV and AIDS, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 57 citations in OpenAlex.
- HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.PloS one · 2016Trial
- Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients.PLoS pathogens · 2012Trial
- Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains.Nature communications · 2024Article
- Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates.Vaccines · 2022Article
- A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.Nature medicine · 2021Article
- Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics.PLoS pathogens · 2019Article
- HIV prevention & treatment strategies - Current challenges & future prospects.The Indian journal of medical research · 2018Article
- Identification and specificity of broadly neutralizing antibodies against HIV.Immunological reviews · 2017Review
- Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production.Human vaccines & immunotherapeutics · 2016Article
- Designing synthetic vaccines for HIV.Expert review of vaccines · 2015Review
- Human immunodeficiency virus vaccines.Infectious disease clinics of North America · 2014Review
- Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein.Journal of biomedical science · 2014Article
- Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.Cell host & microbe · 2013Article
- Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.Journal of virology · 2013Article
- Ultrasensitive Analysis of Binding Affinity of HIV Receptor and Neutralizing Antibody Using Solution-Phase Electrochemiluminescence Assay.Journal of electroanalytical chemistry (Lausanne, Switzerland) · 2013Article
- Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.Journal of virology · 2012Review
- Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design.Trends in microbiology · 2012Review
- Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment.Immunology letters · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThis review describes some of the major obstacles that have impeded progress in the development of an effective neutralizing antibody-based HIV-1 vaccine and explains why it may be possible to overcome these obstacles. A renewed interest in the B-cell response in HIV-1-infected individuals is emphasized. RECENT
findingsNew assay technologies and access to large numbers of clinical specimens have permitted a detailed assessment of the neutralizing antibody response in HIV-1-infected individuals. Recent studies have demonstrated that B cells can be stimulated to generate high titers of broadly cross-reactive neutralizing antibodies against multiple genetic subtypes of the virus. Preliminary evidence suggests that some of these antibodies are directed against epitopes in the CD4 binding site on monomeric gp120, whereas many others are directed against epitopes that remain to be identified. SUMMARY: The rationale for pursuing an effective neutralizing antibody-based HIV-1 vaccine is strengthened by the recent demonstration of potent neutralizing antibody responses in a subset of HIV-1-infected individuals. Information on how this response develops and what epitopes are targeted could provide the insights that are needed to design improved vaccine strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.